- Home
- HCVI vs TLSI Comparison
HCVI vs TLSI Comparison
Compare HCVI & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCVI
- TLSI
- Stock Information
- Founded
- HCVI 2021
- TLSI 2010
- Country
- HCVI United States
- TLSI United States
- Employees
- HCVI N/A
- TLSI N/A
- Industry
- HCVI Blank Checks
- TLSI Medical Specialities
- Sector
- HCVI Finance
- TLSI Health Care
- Exchange
- HCVI Nasdaq
- TLSI Nasdaq
- Market Cap
- HCVI 176.6M
- TLSI 166.8M
- IPO Year
- HCVI 2021
- TLSI N/A
- Fundamental
- Price
- HCVI $10.66
- TLSI $4.73
- Analyst Decision
- HCVI
- TLSI Strong Buy
- Analyst Count
- HCVI 0
- TLSI 2
- Target Price
- HCVI N/A
- TLSI $14.00
- AVG Volume (30 Days)
- HCVI 33.9K
- TLSI 76.8K
- Earning Date
- HCVI 01-01-0001
- TLSI 11-12-2024
- Dividend Yield
- HCVI N/A
- TLSI N/A
- EPS Growth
- HCVI N/A
- TLSI N/A
- EPS
- HCVI N/A
- TLSI N/A
- Revenue
- HCVI N/A
- TLSI $24,736,000.00
- Revenue This Year
- HCVI N/A
- TLSI $61.24
- Revenue Next Year
- HCVI N/A
- TLSI $47.32
- P/E Ratio
- HCVI N/A
- TLSI N/A
- Revenue Growth
- HCVI N/A
- TLSI 67.75
- 52 Week Low
- HCVI $10.30
- TLSI $3.32
- 52 Week High
- HCVI $11.47
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- HCVI 60.14
- TLSI 36.52
- Support Level
- HCVI $10.62
- TLSI $4.80
- Resistance Level
- HCVI $10.66
- TLSI $5.32
- Average True Range (ATR)
- HCVI 0.01
- TLSI 0.34
- MACD
- HCVI 0.00
- TLSI -0.02
- Stochastic Oscillator
- HCVI 100.00
- TLSI 3.06
About HCVI Hennessy Capital Investment Corp. VI
Hennessy Capital Investment Corp VI is a shell company.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.